Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584821 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL31603219 | 0.88 | ALDH1A1 (0.41) | ALDH1A1TSHRMEN1KMT2AL3MBTL1 | |
| SCHEMBL1446404 | 0.87 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL1446403 | 0.87 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL4274093 | 0.87 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL13598441 | 0.87 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL14145046 | 0.87 | CYP1A2 (0.40) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL23291088 | 0.84 | ALDH1A1 (0.36) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL24090888 | 0.84 | ALDH1A1 (0.36) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL16040563 | 0.84 | CHRM2 (0.39) | CHRM2CHRM1CHRM3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | CHRM2 1192/4885CHRM1 365/4885CHRM3 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.